Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

Dasatinib is a BCR-ABL inhibitor with 325-fold higher potency than imatinib against unmutated BCR-ABL in vitro. Imatinib failure is commonly caused by BCR-ABL mutations. Here, dasatinib efficacy was analyzed in patients recruited to phase 2/3 trials with chronic-phase chronic myeloid leukemia with o...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood
Glavni autori: Müller, Martin C., Cortes, Jorge E., Kim, Dong-Wook, Druker, Brian J., Erben, Philipp, Pasquini, Ricardo, Branford, Susan, Hughes, Timothy P., Radich, Jerald P., Ploughman, Lynn, Mukhopadhyay, Jaydip, Hochhaus, Andreas
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2009
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4916940/
https://ncbi.nlm.nih.gov/pubmed/19779040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-04-214221
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items